Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...